genedrive plc

("genedrive" or the "Company")

North West Anglia Foundation NHS Trusts' Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that the Genedrive® CYP2C19-ID Kit has been implemented into the Hyperacute and Acute Stroke Units of Peterborough City Hospital Acute Stroke Centre for routine clinical use.

Hyperacute Stroke units ("HASUs") and Acute Stroke Units ("AUs") are part of the UK's Integrated Stroke Delivery Network, where care typically covers the first 72 hours after admission, with the aim that every patient with acute stroke should gain rapid access to a stroke unit in under 4 hours, and receive an early multidisciplinary assessment¹.

Peterborough City Hospital provides care to approximately 900 stroke patients per annum and is part of North West Anglia Foundation NHS Trust Acute Stroke Centre. The implementation seeks initially to provide genotype-guided optimisation of prescription of antiplatelet drugs to patients presenting with recurrent ischaemic strokes or transient ischaemic attack as well as to young stroke patients aged 18 to 55 within the North West Anglia NHS Foundation Trust Acute Stroke Centre region.

Dr Gino Miele, CEO of genedrive plc, said: "We are delighted with the successful implementation of our rapid CYP2C19 genotyping technology in Peterborough City Hospital, this represents a further milestone in our commercialisation strategy, which continues to strengthen our rapid pharmacogenetic positioning strategy in emergency care more broadly.  We look forward to growing implementation of our CYP2C19 test in the UK NHS and internationally, enabling significant improvement of patient outcomes whilst also offering substantial resource savings to pressured healthcare systems."

Professor Radim Licenik, Consultant Stroke Physician, Clinical Lead for Stroke Service and President of the Society of Czech & Slovak Doctors in the United Kingdom, said: "We are delighted to bring the benefit of this novel technology to Stroke patients in our region. Effective clinical management of neurologic stroke relies in part on optimising the efficacy of anti-platelets prescribed, and within a timeframe that is served only by rapid genetic testing technologies such as this. The implementation will help us to formulate a personalised optimal treatment plan for our stroke patients, that we hope will prevent future strokes and save lives."

1.    https://www.england.nhs.uk/wp-content/uploads/2021/05/stroke-service-model-may-2021.pdf

For further details please contact:

About genedrive plc (http://www.genedriveplc.com).

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.  The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.